Title:Nanosized Tamoxifen-Porphyrin-Glucose [TPG] Conjugate: Novel Selective Anti-breast-cancer Agent, Synthesis and In Vitro Evaluations
Volume: 9
Issue: 4
Author(s): Ali Jabbari Arabzadeh, Mehdi Shafiee Ardestani, Abolfazl Dashtbani-Roozbehani, Seyed Ali Delbaz, Mohammad Shafiee Alavidjeh, Hadi Fathi Moghaddam, Alireza Azizi Saraji, Mahmood Alaei-Beirami, Soheila Hekmat, Massoud Amanlou, Mehdi Hajmohammadi, Seyed Mehdi Sadat, Seyed Esmaeil Sadat Ebrahimi, Masoud Ghorbani, Mohammad Reza Aghasadeghi, Seyed Davar Siadat and Zahra Heidari
Affiliation:
Keywords:
Breast cancer, tamoxifen, porphyrin, glucosamine, N-demethylation, human mammary cancer cell line [MCF- 7]
Abstract: Tumor and especially breast cancer is among the most common causes of death worldwide. Finding novel
nanosized therapeutic compounds have important role to decrease the chance of death and increase the survival. Cancer
cells are highly attractive to glucose [with a nanosize bimolecular structure 1nm] as an energy source more than normal
cell and nanosized therapeutics due to possessing different pharmacokinetic and pharmacodynamic have advantageous
over classical dosage forms in cancer therapy. The aim of the study was to synthesize Glucosamin-Porphyrin-Tamoxifen
[TPG] nanosized complex as a novel selective biocompatible anti breast cancer agent. After the synthesis procedure, this
complex was purified and then tested In Vitro on breast cancer cells [MCF-7] in the absence or presence of the red light
and found totally successful. The results showed a good anti breast cancer activity mediated by the activation of TNF-α
and necrosis/apoptosis pathways for the nanosized complex with no alteration effects on blood PT/APTT and glucose or
hexokinase levels/ activity. TPG nanoconjugate seems to be very good opponents to current anti breast cancer drugs and
needs to be further investigated in near future.
